RepliCel Life Sciences Inc. (TSXV:RP)

Canada flag Canada · Delayed Price · Currency is CAD
0.0150
+0.0050 (50.00%)
Inactive · Last trade price on Feb 28, 2025
-72.73%
Market Cap 209.32K
Revenue (ttm) 353.74K
Net Income (ttm) 1.37M
Shares Out n/a
EPS (ttm) 0.02
PE Ratio 0.15
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 269,000
Average Volume 43,160
Open 0.0100
Previous Close 0.0100
Day's Range 0.0100 - 0.0150
52-Week Range 0.0100 - 0.0650
Beta 0.96
RSI 59.22
Earnings Date Apr 30, 2025

About RepliCel Life Sciences

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company’s product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degenerati... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Andrew Schutte
Employees 1
Stock Exchange TSX Venture Exchange
Ticker Symbol RP
Full Company Profile

Financial Performance

In 2023, RepliCel Life Sciences's revenue was 353,735, a change of 0.00% compared to the previous year's 353,735. Losses were -311,734, -58.06% less than in 2022.

Financial Statements

News

There is no news available yet.